Phase I clinical trials in healthy subjects and patients with PD found Cinpanemab/α-synuclein complex formation in plasma [9] and dose-dependent reduction of serum α-synuclein levels by Prasinezumab [10]. This evidence concerns the gene SNCA and Parkinson disease.